Latest news with #BioHarvest
Associated Press
6 days ago
- Business
- Associated Press
BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles
Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ('BioHarvest' or the 'Company'), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on . Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike. Each individually packaged VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12 mg of Piceid resveratrol, which has been clinically shown to increase arterial dilation. This arterial dilation improves blood flow, delivering more oxygen and nutrients to the body's muscles, tissues, and cells, improving physical energy and mental alertness.* 'Our customers lead dynamic, high-performance lives, and they deserve a product that meets the highest standards for efficacy, safety and ease of use,' said Ilan Sobel, CEO of BioHarvest. 'The launch of VINIA® DailyChews 2x Formula - with Informed Sport certification - marks a major milestone as we expand into the athlete and fitness enthusiast segment of the multi-billion-dollar nutraceuticals market and address a younger consumer base. In addition, our new international ecommerce platform enables global orders, so that customers in countries which allow importation of supplements, such as the UK and Australia, can now have VINIA® products delivered directly to their doorstep with local tax and import fee calculations handled automatically on the backend. 'This launch complements our growing VINIA® Inside portfolio, which includes the core capsule business and hot beverage line of teas and coffees, reflecting our broader strategy to meet increasing global demand for plant-based, science-backed solutions,' concluded Sobel. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. About Informed Sport Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit . Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. BioHarvest Corporate Contact: Dave Ryan, VP Investor Relations +1 (604) 622-1186 [email protected] Investor Relations Contact: Lucas A. Zimmerman Managing Director MZ Group - MZ North America +1 (949) 259-4987 [email protected] To view the source version of this press release, please visit
Yahoo
6 days ago
- Business
- Yahoo
BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles
Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike. Each individually packaged VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12 mg of Piceid resveratrol, which has been clinically shown to increase arterial dilation. This arterial dilation improves blood flow, delivering more oxygen and nutrients to the body's muscles, tissues, and cells, improving physical energy and mental alertness.* "Our customers lead dynamic, high-performance lives, and they deserve a product that meets the highest standards for efficacy, safety and ease of use," said Ilan Sobel, CEO of BioHarvest. "The launch of VINIA® DailyChews 2x Formula - with Informed Sport certification - marks a major milestone as we expand into the athlete and fitness enthusiast segment of the multi-billion-dollar nutraceuticals market and address a younger consumer base. In addition, our new international ecommerce platform enables global orders, so that customers in countries which allow importation of supplements, such as the UK and Australia, can now have VINIA® products delivered directly to their doorstep with local tax and import fee calculations handled automatically on the backend. "This launch complements our growing VINIA® Inside portfolio, which includes the core capsule business and hot beverage line of teas and coffees, reflecting our broader strategy to meet increasing global demand for plant-based, science-backed solutions," concluded Sobel. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. About Informed Sport Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. BioHarvest Corporate Contact:Dave Ryan, VP Investor Relations+1 (604) 622-1186info@ Investor Relations Contact:Lucas A. ZimmermanManaging DirectorMZ Group - MZ North America+1 (949) 259-4987BHST@ To view the source version of this press release, please visit
Associated Press
21-05-2025
- Business
- Associated Press
BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process Rehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ('BioHarvest' or the 'Company'), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market. Ahead of the signing of this Stage 1 contract, BioHarvest leveraged its advanced AI-assisted research capabilities to identify the specific plant species most likely to develop into the required cell bank for future efficient production of the targeted fragrance and scent molecules. Stage 1 of the contract utilizes the Company's proprietary Botanical Synthesis platform to mirror, magnify and multiply the plant's targeted cells in petri dishes. A successful outcome of Stage 1 would be a customer decision to advance the compound to Stage 2, which involves production of the compound in liquid media, a necessary step towards potential future volume manufacturing. The agreement is structured with milestone-based payments and includes a non-disclosure agreement covering Stage 1. This new contract builds on BioHarvest's growing CDMO portfolio and demonstrates the versatility of its platform to address new verticals, including the multi-billion-dollar fragrance and scents market. Ilan Sobel, CEO of BioHarvest, commented: 'This agreement expands the reach of our Botanical Synthesis platform into the high-value fragrance space, adding to our growing pipeline of pharmaceutical and nutrition-focused CDMO projects. Fragrance compounds like these drive billions in global sales, and this contract is further validation of BioHarvest's ability to deliver scalable, high-impact solutions across industries whilst playing an important role in conserving threatened rare plant species and protecting the planet for generations to come. Combined with the strong commercial performance of our nutraceutical division, it is clear that our Botanical Synthesis platform has matured into a transformative technology reshaping access to the world's most valuable plant-based compounds.' Dr. Zaki Rakib, Chairman and President of the CDMO Services Division, concluded: 'The successful commercialization of these fragrance compounds could represent a breakthrough in how highly sought-after botanical products are produced. Every CDMO engagement strengthens our AI-driven discovery capabilities, and we are excited to launch this Stage 1 partnership with such a respected partner. This marks an exciting first step for BioHarvest into the global fragrance and scents market.' About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. BioHarvest Corporate Contact: Dave Ryan, VP Investor Relations +1 (604) 622-1186 [email protected] Investor Relations Contact: Lucas A. Zimmerman Managing Director MZ Group - MZ North America +1 (949) 259-4987 [email protected] To view the source version of this press release, please visit
Associated Press
01-05-2025
- Business
- Associated Press
BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time
Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ('BioHarvest' or the 'Company'), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025. Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on Thursday, May 15, 2025 to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information: First Quarter 2025 Earnings Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. Eastern time U.S./Canada Dial-in: 1-877-300-8521 International Dial-in: 1-412-317-6026 Conference ID: 2552254 Webcast: BHST Q1 2025 Earnings Conference Call Please dial in at least 10 minutes before the start of the call to ensure timely participation. A telephone playback of the call will be available through Thursday, May 29, 2025. To listen, call 1-844-512-2921 within the United States and Canada or 1-412-317-6671 when calling internationally, using replay pin number 10198733. A webcast replay will also be available at the webcast link above. About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. BioHarvest Corporate Contact: Dave Ryan, VP Investor Relations +1 (604) 622-1186 [email protected] Investor Relations Contact: Lucas A. Zimmerman Managing Director MZ Group - MZ North America +1 (949) 259-4987 [email protected] To view the source version of this press release, please visit
Yahoo
06-03-2025
- Business
- Yahoo
BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 37th Annual Roth Conference taking place on March 16-18, 2025. CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event. 37th Annual Roth Conference for Growth CompaniesDate: March 16-18, 2025Location: Laguna Cliffs Marriott Resort & Spa - Dana Point, CAFormat: 1x1s Meetings Sobel said: "I am pleased to announce our invitation to the 37th Annual Roth Conference, which is a high-profile opportunity to showcase BioHarvest's transformative growth story. Following our recent Nasdaq listing and the launch of our CDMO Services Division last year, we are well positioned to execute on our mission to commercialize life-changing, plant-based compounds. These efforts have resulted in major milestones in our direct-to-consumer business, where we recently announced that VINIA had reached $50 Million in cumulative sales, and in our CDMO Services division, where we are conducting research on impactful plant-based solutions for our industry partners in the pharmaceutical, nutraceutical, cosmetics, and nutrition sectors." Registration is mandatory for conference participation. For more information or to schedule a meeting with management, please contact MZ Group at BHST@ About BioHarvest Sciences Inc. BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit Forward-Looking Statements This press release may contain "forward-looking statements". "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and any other risks identified in other filings made by the Company with the Securities and Exchange Commission. This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents. BioHarvest Corporate Contact:Dave Ryan, VP Investor Relations (604) 622-1186info@ Investor Relations Contact:Lucas A. ZimmermanManaging DirectorMZ Group - MZ North America(949) 259-4987BHST@ To view the source version of this press release, please visit Sign in to access your portfolio
